These results highlight the potential of NAT10‐2023 as a promising therapeutic agent for targeting the NAT10‐SMAD3 regulatory axis in HCC, paving the way for new therapeutic strategies in the management of this aggressive cancer. This evidence concerns the gene SMAD3 and hepatocellular carcinoma.